1,369
Views
1
CrossRef citations to date
0
Altmetric
Review Article: Clinical Oncology

Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms

, , , , , ORCID Icon, , , , , , , , , & ORCID Icon show all
Pages 431-437 | Received 06 Mar 2023, Accepted 29 Apr 2023, Published online: 16 May 2023
 

Abstract

Lung neuroendocrine neoplasms (NEN) are a heterogeneous population of neoplasms with different pathology, clinical behavior, and prognosis compared to the more common lung cancers. The diagnostic work-up and treatment of patients with lung- NEN has undergone major recent advances and new methods are currently being introduced into the clinic. These Nordic guidelines summarize and update the Nordic Neuroendocrine Tumor Group’s current view on how to diagnose and treat lung NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients. This review reflects our view of the current state of the art of diagnosis and treatment of patients with lung-NEN. Small cell lung carcinoma (SCLC) is not included in these guidelines.

Disclosure statement

Speaker fee: Medtronic, AMBU, Medela, AstraZeneca. Adv. Board: AstraZeneca, Roche, MSD og BMS.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.